{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:57:53Z","timestamp":1791219473948,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n There is interest in reducing long-term benzodiazepine prescribing given harms associated with use, but the cumulative risks or benefits of discontinuation are unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify the association of benzodiazepine discontinuation with mortality and other adverse events among patients prescribed stable long-term benzodiazepine therapy, stratified by baseline opioid exposure.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This comparative effectiveness study with a trial emulation approach included data from a US commercial insurance database between January 1, 2013, and December 31, 2017. Eligible participants were adults with stable long-term benzodiazepine prescription treatment. Data were analyzed between December 2022 and November 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Benzodiazepine discontinuation, defined as no benzodiazepine prescription coverage for 31 consecutive days identified during a 6-month grace period after baseline.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Mortality during 12 months of follow-up; secondary outcomes included nonfatal overdose, suicide attempt or self-inflicted injury, suicidal ideation, and emergency department use, identified in medical claims. Inverse probability weighting was used to adjust for baseline confounders that potentially affected treatment assignment and censoring due to death or disenrollment. Primary analysis used an intention-to-treat approach; a secondary per-protocol analysis estimated associations after accounting for nonadherence. Analyses were stratified by opioid use.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included 213\u202f011 (136\u202f609 female [64.1%]; mean [SD] age, 62.2 [14.9] years; 2953 Asian [1.4%], 18\u202f926 Black [8.9%], 22\u202f734 Hispanic [10.7%], and 168\u202f398 White [60.2%]) and 140\u202f565 (91\u202f811 female [65.3%]; mean [SD] age, 61.1 [13.2] years; 1319 Asian [0.9%], 15\u202f945 Black [11.3%], 11\u202f989 Hispanic [8.5%], and 111\u202f312 White [79.2%]) patients with stable long-term benzodiazepine use without and with opioid exposure, respectively. Among the nonopioid exposed, the adjusted cumulative incidence of death after 1 year was 5.5% (95% CI, 5.4%-5.8%) for discontinuers, an absolute risk difference of 2.1 percentage points (95% CI, 1.9-2.3 percentage points) higher than for nondiscontinuers. The mortality risk was 1.6 (95% CI, 1.6-1.7) times that of nondiscontinuers. Among those with opioid exposure, the adjusted cumulative incidence of death was 6.3% (95% CI, 6.0%-6.6%) for discontinuers, an absolute risk difference of 2.4 percentage points (95% CI, 2.2-2.7 percentage points) higher than for nondiscontinuers and a mortality risk 1.6 (95% CI, 1.5-1.7) times that of nondiscontinuers. Cumulative incidence of secondary outcomes was also higher among discontinuers.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study identifies small absolute increases in risk of harms among patients with stable long-term prescription benzodiazepine treatment who appear to discontinue relative to continuing treatment, including those with and without recent prescription opioid exposure. Policy broadly promoting benzodiazepine discontinuation may have unintended risks.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.48557","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T11:02:30Z","timestamp":1703070150000},"page":"e2348557","source":"Crossref","is-referenced-by-count":52,"title":["Benzodiazepine Discontinuation and Mortality Among Patients Receiving Long-Term Benzodiazepine Therapy"],"prefix":"10.1001","volume":"6","author":[{"given":"Donovan T.","family":"Maust","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Michigan, Ann Arbor"},{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kierstdea","family":"Petzold","sequence":"additional","affiliation":[{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Strominger","sequence":"additional","affiliation":[{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Myra","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"},{"name":"Center for Statistical Consultation and Research, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S. B.","family":"Bohnert","sequence":"additional","affiliation":[{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"},{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"issue":"2","key":"zoi231415r1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine use and misuse among adults in the United States.","volume":"70","author":"Maust","year":"2019","journal-title":"Psychiatr Serv"},{"issue":"4","key":"zoi231415r2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","article-title":"Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013.","volume":"106","author":"Bachhuber","year":"2016","journal-title":"Am J Public Health"},{"issue":"7","key":"zoi231415r3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/jama.2013.272","article-title":"Pharmaceutical overdose deaths, United States, 2010.","volume":"309","author":"Jones","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"zoi231415r8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","article-title":"Treatment of Benzodiazepine Dependence.","volume":"376","author":"Soyka","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi231415r9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMp1715050","article-title":"Our other prescription drug problem.","volume":"378","author":"Lembke","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi231415r10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.","volume":"28","author":"Baldwin","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"14","key":"zoi231415r11","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1001\/archinte.164.14.1567","article-title":"Benzodiazepine use and hip fractures in the elderly: who is at greatest risk?","volume":"164","author":"Wagner","year":"2004","journal-title":"Arch Intern Med"},{"issue":"21","key":"zoi231415r12","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/archinternmed.2009.357","article-title":"Meta-analysis of the impact of 9 medication classes on falls in elderly persons.","volume":"169","author":"Woolcott","year":"2009","journal-title":"Arch Intern Med"},{"issue":"5","key":"zoi231415r13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4088\/JCP.08m04325","article-title":"Benzodiazepine use and driving: a meta-analysis.","volume":"70","author":"Rapoport","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"zoi231415r14","doi-asserted-by":"publisher","first-page":"h2698","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.","volume":"350","author":"Park","year":"2015","journal-title":"BMJ"},{"issue":"8","key":"zoi231415r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.26523","article-title":"Comparative effectiveness of opioid tapering or abrupt discontinuation vs no dosage change for opioid overdose or suicide for patients receiving stable long-term opioid therapy.","volume":"5","author":"Larochelle","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi231415r16","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s11606-019-05301-2","article-title":"Mortality after discontinuation of primary care\u2013based chronic opioid therapy for pain: a retrospective cohort study.","volume":"34","author":"James","year":"2019","journal-title":"J Gen Intern Med"},{"key":"zoi231415r17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jsat.2019.05.001","article-title":"Opioid medication discontinuation and risk of adverse opioid-related health care events.","volume":"103","author":"Mark","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"zoi231415r18","doi-asserted-by":"publisher","first-page":"m283","DOI":"10.1136\/bmj.m283","article-title":"Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation.","volume":"368","author":"Oliva","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"zoi231415r19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/j.pain.0000000000002298","article-title":"Patient outcomes after opioid dose reduction among patients with chronic opioid therapy.","volume":"163","author":"Hallvik","year":"2022","journal-title":"Pain"},{"issue":"8","key":"zoi231415r20","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s11606-007-0205-5","article-title":"Older patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study.","volume":"22","author":"Cook","year":"2007","journal-title":"J Gen Intern Med"},{"issue":"4","key":"zoi231415r21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1049732315576496","article-title":"\u201cI\u2019m not waving, I\u2019m drowning\u201d: an autoethnographical exploration of biographical disruption and reconstruction during recovery from prescribed benzodiazepine use.","volume":"26","author":"Fixsen","year":"2016","journal-title":"Qual Health Res"},{"issue":"3","key":"zoi231415r22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","article-title":"The diagnosis and management of benzodiazepine dependence.","volume":"18","author":"Ashton","year":"2005","journal-title":"Curr Opin Psychiatry"},{"issue":"11","key":"zoi231415r23","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/add.1994.89.issue-11","article-title":"The benzodiazepine withdrawal syndrome.","volume":"89","author":"P\u00e9tursson","year":"1994","journal-title":"Addiction"},{"issue":"8","key":"zoi231415r24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"6","key":"zoi231415r27","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamainternmed.2014.949","article-title":"Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial.","volume":"174","author":"Tannenbaum","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi231415r28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1192\/bjp.bp.113.134650","article-title":"Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care.","volume":"204","author":"Vicens","year":"2014","journal-title":"Br J Psychiatry"},{"key":"zoi231415r29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1192\/bjp.182.6.498","article-title":"Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial.","volume":"182","author":"Voshaar","year":"2003","journal-title":"Br J Psychiatry"},{"issue":"1","key":"zoi231415r30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/fampra\/cmi065","article-title":"Predictors of discontinuation of benzodiazepine prescription after sending a letter to long-term benzodiazepine users in family practice.","volume":"23","author":"Gorgels","year":"2006","journal-title":"Fam Pract"},{"issue":"2","key":"zoi231415r31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1176\/appi.ajp.161.2.332","article-title":"Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia.","volume":"161","author":"Morin","year":"2004","journal-title":"Am J Psychiatry"},{"key":"zoi231415r32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jclinepi.2017.11.021","article-title":"Electronic medical records can be used to emulate target trials of sustained treatment strategies.","volume":"96","author":"Danaei","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"zoi231415r33","doi-asserted-by":"publisher","first-page":"j760","DOI":"10.1136\/bmj.j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"zoi231415r34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1192\/bjp.189.3.213","article-title":"Strategies for discontinuing long-term benzodiazepine use: meta-analysis.","volume":"189","author":"Voshaar","year":"2006","journal-title":"Br J Psychiatry"},{"key":"zoi231415r35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40360-015-0019-8","article-title":"Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review.","volume":"16","author":"Pollmann","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"key":"zoi231415r25","volume-title":"The American Psychiatric Publishing textbook of substance abuse treatment","author":"Galanter","year":"2008","edition":"4th ed"},{"key":"zoi231415r26","volume-title":"The Comparative Effectiveness, Safety, and Cost of Oral P2Y12 Antiplatelet Agents Following Acute Coronary Syndromes","author":"Belviso","year":"2020"},{"key":"zoi231415r4","unstructured":"National Institute on Drug Abuse, US Department of Health and Human Services. National Drug Overdose Deaths Involving Benzodiazepines, by Opioid Involvement, Number Among All Ages, 1999-2020. Accessed August 4, 2022. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates#:~:text=Drug%20overdose%20deaths%20involving%20benzodiazepines%20has%20steadily%20increased%20from%201%2C135,and%20rose%20again%20to%2012%2C290"},{"key":"zoi231415r5","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. August 31, 2016. Accessed May 10, 2019. https:\/\/www.fda.gov\/media\/99761\/download"},{"key":"zoi231415r6","unstructured":"U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. September 23, 2020. Accessed October 15, 2020. https:\/\/www.fda.gov\/media\/142368\/download"},{"key":"zoi231415r7","unstructured":"US Food and Drug Administration. Cooperative Agreement to Support an Evidence-Based Clinical Practice Guideline for the Safe Tapering of Benzodiazepines (U01) Clinical Trials Not Allowed. Posted May 31, 2022. Accessed August 11, 2023. https:\/\/grants.nih.gov\/grants\/guide\/rfa-files\/RFA-FD-22-027.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2813161\/maust_2023_oi_231415_1702412417.00606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T11:02:35Z","timestamp":1703070155000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2813161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.48557","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]}}}